A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Protocol No
SUTRO-STRO-002-GM1
Principal Investigator
Denise Uyar
Phase
I
Summary
We want to find out more about the side effects (problems and symptoms) of a new drug for STRO-002 and what doses of STRO-002 are safe for people to take.
Description
Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: